Amneal Pharmaceuticals announces that it has received New Drug Application approval from the US FDA for its presentation of potassium phosphates in 0.9% sodium chloride injection intravenous (IV) ready-to-use (RTU) bags. This sterile presentation is made to reduce the compounding steps for clinicians. Potassium phosphates in sodium chloride injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated. The product is available as a single-dose infusion bag and is formulated without preservatives. The bag is constructed with natural rubber, is latex-free, and can be stored at room temperature.